DC-U4106 is a USP8 targeting inhibitor with the K_dvalue of 4.7 μM and the IC₅₀ value of 1.2 μM. DC-U4106 can target the ubiquitin pathway and facilitate the degradation of Erα. DC-U4106 inhibits tumor growth with minimal toxicity and has the potential for the research of breast cancer^[1].

Kd: 4.7 μM (USP8), IC50: 1.2 μM (USP8)^[1].

DC-U4106 (1.2-45.2 μM) inhibits USP8 and USP2 with the IC₅₀ values of 1.2 μM and 58.4 μM, respectively, and no activity in USP7^[1].
DC-U4106 (0-7 μM, 24 hours) reduces mRNA levels of ERα and PR^[1].
DC-U4106 (0-5 μM, 24 hours) can regulate the RTK pathway related proteins and the expression of ERα and PR proteins^[1].
DC-U4106 (0-5 μM, 12 hours) can induce apoptosis and inhibit cell proliferation^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

DC-U4106 (intraperitoneal injection, 5 mg/kg or 20 mg/kg, every 2 days, 14 days) inhibits the proliferation of tumors and no significantly effects on body weight, organ morphology and structure in BALB/c nude mice^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

525.56

C₂₉H₂₇N₅O₅

2410534-62-0

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yucheng Tian, et al. Discovery of Potent Small-Molecule USP8 Inhibitors for the Treatment of Breast Cancer through Regulating ERα Expression. J Med Chem. 2022 Jul 5.